INTRODUCTION
There is considerable debate as to the best means of safely establishing immediate control of acute bleeding from oesophageal varices. Oesophageal tamponade has been shown to be an effective means of control of bleeding 1'2'3 but respiratory complications may arise and patient tolerance is poor. Vasopressin has been the mainstay of drug treatment over the past thirty years but doubts have been raised as to its efficacy 4 and serious cardiac side-effects may occur. It has been suggested that the addition to vasopressin of a vasodilator such as nitroglycerin may reduce the incidence of side-effects 5'6 The characteristics of the variceal bleeds included in this trial in terms of the number of first bleeds from varices, the time from its initial manifestation and the amount of blood given before admission to the trial were similar in the two groups (Table 3) . In the SMS group 14 of 20 patients had no further bleeding at 24 hours (p < 0.5 cf. OT group) and 10 patients had had no bleeding at 48 hours. In 8 episodes of variceal haemorrhage were controlled by somatostatin for 48 hours, although inferior to the results of the Liverpool group1, who found that variceal haemorrhage was controlled for 24 hours by somatostatin infusion in all 10 patients in whom it was employed. Since we have shown a deterioration in control of bleeding with time, the difference in results may be due to the longer trial period in both the study by Kravetz and colleagues 9 and the present study. In the study of Jenkins and co-workers1, somatostatin was only given to ten patients and the small numbers in all of the studies 9'1 may help account for the apparent differences. In more recent placebo controlled studies, one multicentre trial TM failed to show significant benefit in that in the 30 hour study period 65% of the patients given somatostatin stopped bleeding as opposed to 83% of those given placebo. Despite the somewhat surprising "success" of placebo, transfusion requirements and mortality rates were similar in the two groups. In a trial from the Royal Free Hospital, London, somatostatin proved significantly more effective than placebo in controlling bleeding (64% versus 41%) and when bleeding recurred it did so earlier in the placebo group15. Somatostatin significantly reduced blood and plasma transfusion requirement and halved the need for balloon tamponade. Although it was concluded that somatostatin was safe and more effective at controlling bleeding than placebo, 30 day mortality was not affected.
In our situation we felt that a 48 hour trial comparing SMS 201-995 infusion with placebo would be difficult to justify and we have therefore compared SMS 201-995 infusion with the previous best means of immediate treatment in our department2. The fact that SMS 201-995 infusion was carried out for 48 hours is balanced by the fact that the Minnesota tube was left in place for this period so that tamponade could be continued if necessary. Although emergency sclerotherapy may be the ideal means of treatment the necessary expertise and facilities are not always immediately available and some means of emergency treatment is essential. Previous controlled trials in variceal bleeding have achieved variable control rates with placebo-ranging from 25% at 24 hours6, through 37% at 8 hours 7 to 45% at 24 hoursTM. Strict comparison of trials is difficult because of differences in the severity of bleeds included, in the accuracy of diagnosis, in the means of conservative treatment, in the length of the trial period and in the methods used to assess control of haemorrhage. Furthermore, although the number of bleeding episodes in the current trial is similar to other recent controlled trials9'1, it must not be forgotten that the number of variceal bleeds required in a controlled trial to achieve even 50% power, assuming a substantial difference in bleeding control rates, is more than two hundred.
Although oesophageal tamponade has proved an effective means of controlling variceal bleeding in the past, it has several potential serious side-effects and a comparison of the incidence of side-effects in the two groups in this trial is of considerable importance. In the present study discomfort from the Minnesota tube was a major complaint in In comparing treatments for variceal haemorrhage it is also worth considering that the administration of a drug infusion requires less expertise on the part of the medical and nursing staff than oesophageal tamponade. This may be a significant advantage in hospitals where relatively few patients with variceal bleeding are seen and an SMS 201-995 infusion may facilitate the patient's safe transfer to a specialised centre. The reduction in bleeding control rate with time emphasises that immediate treatment of variceal haemorrhage to control bleeding should be followed rapidly by definitive treatment to prevent rebleeding such as injection sclerotherapy. It is clear in retrospect that this definitive treatment should be performed earlier than 48 hours.
In this trial five patients were excluded because they had been judged to be exsanguinating by the staff of the Accident and Emergency Department and had been treated immediately by oesophageal tamponade, the standard hospital treatment. SMS 201-995 was not available to the A&E staff at that time. This may have excluded some of the severe bleeds from this trial but our strict entry criteria of active variceal bleeding at endoscopy probably also excluded a number of mild variceal bleeds. It may be that oesophageal tamponade will be necessary for the most severe bleeds, although its use was progmatic in the cases described above.
The main aim of this trial was to assess theeffect of SMS 201-995 on bleeding from oesophageal varices and the finding of a higher survival rate in the SMS 201-995 group was unexpected. Stratification to account for liver function was not practical in a small trial and despite randomisation there was a greater number of patients with poor liver function in the tamponade group. Therefore the difference in survival may be artefactual due to the small numbers.
In conclusion, infusion of SMS 201-995 would appear to have certain advantages over oesophageal tamponade for the immediate control of bleeding oesophageal varices, with any reduction in bleeding control being offset by its better tolerability.
However, control deteriorates with time and it is possible that its future role may be in the temporary control of bleeding while the patient is resuscitated before acute injection sclerotherapy is undertaken.
